PRESS RELEASE published on 08/26/2025 at 07:30, 8 months 29 days ago Dermapharm confirms stable business development in H1 2025 and records EBITDA growth in Q2 versus prior-year quarter Dermapharm confirms stable business development in H1 2025 with EBITDA growth in Q2. Full-year guidance for 2025 reiterated. Branded pharmaceuticals main growth driver Revenue Pharmaceuticals EBITDA Growth Dermapharm H1 2025
BRIEF published on 08/12/2025 at 07:35, 9 months 12 days ago Dermapharm Holding SE poursuit sa croissance au deuxième trimestre 2025 Prévisions De Revenus Croissance De L'EBITDA Produits Pharmaceutiques De Marque Dermapharm Performances Du Deuxième Trimestre 2025
BRIEF published on 08/12/2025 at 07:35, 9 months 12 days ago Dermapharm Holding SE Continues Growth in Q2 2025 Revenue Forecast EBITDA Growth Branded Pharmaceuticals Dermapharm Q2 2025 Performance
PRESS RELEASE published on 08/12/2025 at 07:30, 9 months 12 days ago Dermapharm Holding SE remains on projected growth trajectory in Q2 2025 Dermapharm Holding SE reports Q2 2025 results in line with expectations. Confirms full-year guidance of EUR 1,160–1,200 million revenue and EUR 322–332 million EBITDA Pharmaceuticals EBITDA Growth Dermapharm Holding SE Full-year Guidance Q2 2025 Results
BRIEF published on 06/26/2025 at 17:48, 10 months 27 days ago Dermapharm Holding SE Approves EUR 0.90 Dividend Per Share Sustainability Dividend AGM Financial Outlook Dermapharm
BRIEF published on 06/26/2025 at 17:48, 10 months 27 days ago Dermapharm Holding SE approuve un dividende de 0,90 € par action Dividende Durabilité Assemblée Générale Annuelle Perspectives Financières Dermapharm
PRESS RELEASE published on 06/26/2025 at 17:43, 10 months 27 days ago Dermapharm Holding SE: Annual General Meeting resolves dividend distribution of EUR 0.90 per share Dermapharm Holding SE's Annual General Meeting approves divident distribution of EUR 0.90 per share for 2024, confirms 2025 outlook and ratifies Board actions Annual General Meeting Financial Year 2024 Dividend Distribution Dermapharm Holding SE EUR 0.90 Per Share
BRIEF published on 05/15/2025 at 07:35, 1 year ago Dermapharm Holding SE Meets Q1 2025 Expectations, Reinforces Full-Year Forecast Revenue Growth Full-year Guidance EBITDA Decline Branded Pharmaceuticals Dermapharm Q1 2025
BRIEF published on 05/15/2025 at 07:35, 1 year ago Dermapharm Holding SE répond aux attentes du premier trimestre 2025 et renforce ses prévisions pour l'ensemble de l'année Croissance Des Revenus Baisse De L'EBITDA Orientation Pour L'année Entière Produits Pharmaceutiques De Marque Dermapharm T1 2025
PRESS RELEASE published on 05/15/2025 at 07:30, 1 year ago Dermapharm Holding SE performs in line with projections in Q1 2025, confirms full-year guidance Dermapharm Holding SE reports Q1 2025 results in line with projections, confirming full-year guidance. Revenue increases by 1.2% year-on-year to EUR 302.4 million Adjusted EBITDA Revenue Growth Dermapharm Holding SE Full-year Guidance Q1 2025 Results
Published on 05/23/2026 at 19:45, 15 hours 51 minutes ago Golden Minerals Announces Closing of Equity Financing
Published on 05/23/2026 at 03:15, 1 day 8 hours ago UraniumX Approved for Trading on the OTCQB Venture Market and Announces Board Change
Published on 05/23/2026 at 03:00, 1 day 8 hours ago Battery X Metals Reports Up to ~84 km Estimated Driving Range Increase Across Multiple BYD Electric Vehicles Following Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Trials, Demonstrating Performance Improvement Across the World’s Larges
Published on 05/23/2026 at 02:25, 1 day 9 hours ago Battery X Metals Announces up to $2 Million Private Placement Financing and Initiative to Strengthen Balance Sheet
Published on 05/23/2026 at 02:25, 1 day 9 hours ago Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec
Published on 05/24/2026 at 05:55, 5 hours 40 minutes ago The 26th CIFIT to Open in Xiamen This September, Preceded by Successful Guangzhou Roadshow
Published on 05/24/2026 at 05:35, 6 hours ago CGTN: Xizang at 75: Development and culture create a 'miracle on Earth'
Published on 05/23/2026 at 16:30, 19 hours 5 minutes ago HiFS 2026: Upgrading Four Major Digital Finance Solutions to Accelerate Financial Institutions Toward Agentic Banking
Published on 05/23/2026 at 15:57, 19 hours 39 minutes ago EQS-Adhoc: Delivery Hero confirms approach by Uber Technologies’ with respect to potential takeover offer
Published on 05/22/2026 at 22:05, 1 day 13 hours ago Abivax présente ses résultats financiers du T1 2026 et les données à trois ans de l’étude 108, un essai d’extension ouvert de phase 2a/2b évaluant l’obéfazimod après réduction de dose dans la RCH
Published on 05/22/2026 at 19:35, 1 day 16 hours ago PROJET D'EVOLUTION DE SA GOUVERNANCE ET LA NOMINATION D'UN PRESIDENT DU DIRECTOIRE PAR INTERIM
Published on 05/22/2026 at 18:05, 1 day 17 hours ago Déclaration hebdomadaire d'opérations effectuées du 18 au 22 mai 2026
Published on 05/22/2026 at 18:05, 1 day 17 hours ago Disclosure of transactions in own shares from May 18 to May 22, 2026
Published on 05/22/2026 at 12:52, 1 day 22 hours ago Communiqué du Conseil d’administration – Assemblée Générale du 22 mai 2026
Published on 05/22/2026 at 12:52, 1 day 22 hours ago Release from the Board of Directors - Shareholders’ Meeting of May 22, 2026
